Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02092909 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
A Phase 1 study, sponsored by Idera Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02092909 is a Phase 1 study that was terminated before completion, run by Idera Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT02092909, a Phase 1 study, was terminated before completion, sponsored by Idera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 90% of the patients with Waldenström's macroglobulinemia. MYD88 is a key linker protein in the signaling pathway of Toll Like Receptors (TLRs) 7, 8, and 9, and IMO-8400 is an oligonucleotide specifically designed to inhibit TLRs 7,8, and 9. The scientific hypothesis for use of IMO-8400 to treat patients with Waldenström's macroglobulinemia depends on the inhibition of mutant MYD88 signaling in the TLR pathway, thereby interrupting the proliferation of cell populations responsible for the propagation of the disease.
Interventions
- DRUG IMO-8400
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-03 |
| Est. Completion | 2017-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02092909
The ClinicalTrials.gov registry entry for NCT02092909 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idera Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMO-8400 is the first listed.
NCT02092909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02092909 about?
NCT02092909 is a clinical study titled "Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia". Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 90% of the patients with Waldenström's macroglobulinemia. MYD88 is a key linker protein in the signaling pathway of Toll Like Receptors (TLRs) 7, 8, and 9, and IMO-8400 is an oligonucleotide specifi...
What is the current status of trial NCT02092909?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2014-03. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02092909?
The interventions under investigation include: IMO-8400 (DRUG).
Who is sponsoring clinical trial NCT02092909?
This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.